March 06, 2024

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 28, 2024

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

February 12, 2024

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

January 31, 2024

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

January 03, 2024

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

December 20, 2023

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

November 27, 2023

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 06, 2023

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

November 02, 2023

InspireMD to Participate in Upcoming November Investor Conferences

November 01, 2023

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

October 30, 2023

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

October 12, 2023

InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

October 03, 2023

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

August 31, 2023

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

August 08, 2023

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

June 26, 2023

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

May 18, 2023

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 16, 2023

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023

InspireMD Announces Private Placement of Up to $113.6 Million

May 12, 2023

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

May 05, 2023

InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

May 01, 2023

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

April 27, 2023

InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update

March 30, 2023

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 20, 2023

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

March 02, 2023

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

February 14, 2023

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

November 28, 2022

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

November 15, 2022

InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium

November 08, 2022

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

October 25, 2022

InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update

September 13, 2022

InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

August 09, 2022

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

August 02, 2022

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

July 14, 2022

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

June 09, 2022

InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

June 02, 2022

InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

May 10, 2022

InspireMD Reports First Quarter 2022 Financial Results and Business Update

April 28, 2022

InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

March 16, 2022

InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio

March 08, 2022

InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

February 28, 2022

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

February 22, 2022

InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

February 15, 2022

InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

January 27, 2022

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

January 18, 2022

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

November 09, 2021

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 03, 2021

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

October 26, 2021

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

October 13, 2021

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health